Regcon Holdings Company Profile
What is the competitive landscape for REGCON HOLDINGS
REGCON HOLDINGS has fifty-five approved drugs.
Summary for Regcon Holdings
| US Patents: | 0 |
| Tradenames: | 49 |
| Ingredients: | 49 |
| NDAs: | 55 |
Drugs and US Patents for Regcon Holdings
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regcon Holdings | CARVEDILOL | carvedilol | TABLET;ORAL | 078384-002 | Sep 5, 2007 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET;ORAL | 213550-001 | Jul 14, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 202054-001 | Sep 3, 2014 | AT1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 210197-002 | Jan 12, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
